MedTrace Logo

A Study to Investigate Drug Interaction Between D326, D337, and D013 in Healthy Male Subjects

NCT03609606 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2018-10-05

No results posted yet for this study

Summary

A study to investigate drug interaction between D326, D337, and D013 in healthy male subjects

Conditions

Interventions

DRUG

D013, D326 and D337

Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days

DRUG

D013

Daily oral administration of 1 tablet under fasting conditions for 7 days

DRUG

D326 and D337

Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Ji-Young Park, M.D., Ph.D · Department of Pharmacology, College of Medicine/ Department of Clinical Pharmacology&Toxicology, Anam Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-09
Primary Completion
2018-09-14
Completion
2018-09-27

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03609606 on ClinicalTrials.gov